nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—hematologic cancer	0.226	1	CbGaD
Nadolol—ABCB1—Lenalidomide—hematologic cancer	0.0545	0.141	CbGbCtD
Nadolol—ABCB1—Daunorubicin—hematologic cancer	0.0319	0.0826	CbGbCtD
Nadolol—ABCB1—Alitretinoin—hematologic cancer	0.0313	0.0809	CbGbCtD
Nadolol—ABCB1—Imatinib—hematologic cancer	0.0245	0.0633	CbGbCtD
Nadolol—ABCB1—Nilotinib—hematologic cancer	0.0222	0.0575	CbGbCtD
Nadolol—ABCB1—Vinorelbine—hematologic cancer	0.0221	0.057	CbGbCtD
Nadolol—ABCB1—Dasatinib—hematologic cancer	0.0197	0.0508	CbGbCtD
Nadolol—ABCB1—Mitoxantrone—hematologic cancer	0.0194	0.0502	CbGbCtD
Nadolol—ABCB1—Betamethasone—hematologic cancer	0.0173	0.0447	CbGbCtD
Nadolol—ABCB1—Gemcitabine—hematologic cancer	0.0171	0.0443	CbGbCtD
Nadolol—ABCB1—Prednisolone—hematologic cancer	0.0171	0.0442	CbGbCtD
Nadolol—ABCB1—Prednisone—hematologic cancer	0.0161	0.0417	CbGbCtD
Nadolol—ABCB1—Irinotecan—hematologic cancer	0.0153	0.0395	CbGbCtD
Nadolol—ABCB1—Vinblastine—hematologic cancer	0.0136	0.0351	CbGbCtD
Nadolol—ABCB1—Vincristine—hematologic cancer	0.0134	0.0345	CbGbCtD
Nadolol—ABCB1—Cisplatin—hematologic cancer	0.0125	0.0322	CbGbCtD
Nadolol—ABCB1—Etoposide—hematologic cancer	0.0122	0.0317	CbGbCtD
Nadolol—ABCB1—Dexamethasone—hematologic cancer	0.0101	0.026	CbGbCtD
Nadolol—ABCB1—Doxorubicin—hematologic cancer	0.00835	0.0216	CbGbCtD
Nadolol—ABCB1—Methotrexate—hematologic cancer	0.00809	0.0209	CbGbCtD
Nadolol—Decreased appetite—Etoposide—hematologic cancer	7.01e-05	0.000222	CcSEcCtD
Nadolol—Diarrhoea—Ifosfamide—hematologic cancer	6.99e-05	0.000222	CcSEcCtD
Nadolol—Nausea—Vinorelbine—hematologic cancer	6.99e-05	0.000222	CcSEcCtD
Nadolol—Body temperature increased—Cisplatin—hematologic cancer	6.96e-05	0.000221	CcSEcCtD
Nadolol—Asthenia—Irinotecan—hematologic cancer	6.96e-05	0.000221	CcSEcCtD
Nadolol—Asthenia—Mitoxantrone—hematologic cancer	6.96e-05	0.000221	CcSEcCtD
Nadolol—Fatigue—Etoposide—hematologic cancer	6.96e-05	0.000221	CcSEcCtD
Nadolol—Vomiting—Thalidomide—hematologic cancer	6.91e-05	0.000219	CcSEcCtD
Nadolol—Dizziness—Carmustine—hematologic cancer	6.9e-05	0.000219	CcSEcCtD
Nadolol—Constipation—Etoposide—hematologic cancer	6.9e-05	0.000219	CcSEcCtD
Nadolol—Pain—Etoposide—hematologic cancer	6.9e-05	0.000219	CcSEcCtD
Nadolol—Conjunctivitis—Epirubicin—hematologic cancer	6.89e-05	0.000219	CcSEcCtD
Nadolol—Rash—Thalidomide—hematologic cancer	6.85e-05	0.000217	CcSEcCtD
Nadolol—Dermatitis—Thalidomide—hematologic cancer	6.84e-05	0.000217	CcSEcCtD
Nadolol—Dizziness—Alitretinoin—hematologic cancer	6.84e-05	0.000217	CcSEcCtD
Nadolol—Diarrhoea—Vincristine—hematologic cancer	6.82e-05	0.000216	CcSEcCtD
Nadolol—Pain—Prednisolone—hematologic cancer	6.81e-05	0.000216	CcSEcCtD
Nadolol—Sweating—Epirubicin—hematologic cancer	6.8e-05	0.000216	CcSEcCtD
Nadolol—Asthenia—Gemcitabine—hematologic cancer	6.78e-05	0.000215	CcSEcCtD
Nadolol—Dizziness—Ifosfamide—hematologic cancer	6.76e-05	0.000214	CcSEcCtD
Nadolol—Weight increased—Doxorubicin—hematologic cancer	6.7e-05	0.000212	CcSEcCtD
Nadolol—Pruritus—Gemcitabine—hematologic cancer	6.69e-05	0.000212	CcSEcCtD
Nadolol—Vision blurred—Prednisone—hematologic cancer	6.68e-05	0.000212	CcSEcCtD
Nadolol—Nausea—Thiotepa—hematologic cancer	6.67e-05	0.000212	CcSEcCtD
Nadolol—Oedema—Dexamethasone—hematologic cancer	6.64e-05	0.000211	CcSEcCtD
Nadolol—Oedema—Betamethasone—hematologic cancer	6.64e-05	0.000211	CcSEcCtD
Nadolol—Diarrhoea—Irinotecan—hematologic cancer	6.64e-05	0.00021	CcSEcCtD
Nadolol—Diarrhoea—Mitoxantrone—hematologic cancer	6.64e-05	0.00021	CcSEcCtD
Nadolol—Vomiting—Carmustine—hematologic cancer	6.63e-05	0.00021	CcSEcCtD
Nadolol—Insomnia—Triamcinolone—hematologic cancer	6.62e-05	0.00021	CcSEcCtD
Nadolol—Agranulocytosis—Epirubicin—hematologic cancer	6.62e-05	0.00021	CcSEcCtD
Nadolol—Dizziness—Vincristine—hematologic cancer	6.59e-05	0.000209	CcSEcCtD
Nadolol—Rash—Carmustine—hematologic cancer	6.58e-05	0.000209	CcSEcCtD
Nadolol—Dermatitis—Carmustine—hematologic cancer	6.57e-05	0.000208	CcSEcCtD
Nadolol—Vomiting—Alitretinoin—hematologic cancer	6.57e-05	0.000208	CcSEcCtD
Nadolol—Paraesthesia—Triamcinolone—hematologic cancer	6.57e-05	0.000208	CcSEcCtD
Nadolol—Visual impairment—Methotrexate—hematologic cancer	6.56e-05	0.000208	CcSEcCtD
Nadolol—Shock—Dexamethasone—hematologic cancer	6.53e-05	0.000207	CcSEcCtD
Nadolol—Shock—Betamethasone—hematologic cancer	6.53e-05	0.000207	CcSEcCtD
Nadolol—Dyspnoea—Triamcinolone—hematologic cancer	6.53e-05	0.000207	CcSEcCtD
Nadolol—Rash—Alitretinoin—hematologic cancer	6.52e-05	0.000207	CcSEcCtD
Nadolol—Dermatitis—Alitretinoin—hematologic cancer	6.51e-05	0.000206	CcSEcCtD
Nadolol—Vomiting—Ifosfamide—hematologic cancer	6.5e-05	0.000206	CcSEcCtD
Nadolol—Bradycardia—Epirubicin—hematologic cancer	6.48e-05	0.000205	CcSEcCtD
Nadolol—Diarrhoea—Gemcitabine—hematologic cancer	6.47e-05	0.000205	CcSEcCtD
Nadolol—Nausea—Thalidomide—hematologic cancer	6.45e-05	0.000205	CcSEcCtD
Nadolol—Dyspepsia—Triamcinolone—hematologic cancer	6.44e-05	0.000204	CcSEcCtD
Nadolol—Rash—Ifosfamide—hematologic cancer	6.44e-05	0.000204	CcSEcCtD
Nadolol—Dermatitis—Ifosfamide—hematologic cancer	6.44e-05	0.000204	CcSEcCtD
Nadolol—Hyperhidrosis—Betamethasone—hematologic cancer	6.42e-05	0.000204	CcSEcCtD
Nadolol—Hyperhidrosis—Dexamethasone—hematologic cancer	6.42e-05	0.000204	CcSEcCtD
Nadolol—Dizziness—Irinotecan—hematologic cancer	6.42e-05	0.000203	CcSEcCtD
Nadolol—Body temperature increased—Etoposide—hematologic cancer	6.38e-05	0.000202	CcSEcCtD
Nadolol—Conjunctivitis—Doxorubicin—hematologic cancer	6.38e-05	0.000202	CcSEcCtD
Nadolol—Syncope—Prednisone—hematologic cancer	6.36e-05	0.000201	CcSEcCtD
Nadolol—Tinnitus—Methotrexate—hematologic cancer	6.34e-05	0.000201	CcSEcCtD
Nadolol—Vomiting—Vincristine—hematologic cancer	6.33e-05	0.000201	CcSEcCtD
Nadolol—Anorexia—Betamethasone—hematologic cancer	6.33e-05	0.000201	CcSEcCtD
Nadolol—Anorexia—Dexamethasone—hematologic cancer	6.33e-05	0.000201	CcSEcCtD
Nadolol—Asthenia—Cisplatin—hematologic cancer	6.32e-05	0.0002	CcSEcCtD
Nadolol—Fatigue—Triamcinolone—hematologic cancer	6.31e-05	0.0002	CcSEcCtD
Nadolol—Sweating—Doxorubicin—hematologic cancer	6.29e-05	0.000199	CcSEcCtD
Nadolol—Rash—Vincristine—hematologic cancer	6.28e-05	0.000199	CcSEcCtD
Nadolol—Dermatitis—Vincristine—hematologic cancer	6.28e-05	0.000199	CcSEcCtD
Nadolol—Pain—Triamcinolone—hematologic cancer	6.26e-05	0.000198	CcSEcCtD
Nadolol—Loss of consciousness—Prednisone—hematologic cancer	6.23e-05	0.000197	CcSEcCtD
Nadolol—Hypotension—Dexamethasone—hematologic cancer	6.21e-05	0.000197	CcSEcCtD
Nadolol—Hypotension—Betamethasone—hematologic cancer	6.21e-05	0.000197	CcSEcCtD
Nadolol—Nausea—Carmustine—hematologic cancer	6.2e-05	0.000196	CcSEcCtD
Nadolol—Vomiting—Mitoxantrone—hematologic cancer	6.17e-05	0.000196	CcSEcCtD
Nadolol—Vomiting—Irinotecan—hematologic cancer	6.17e-05	0.000196	CcSEcCtD
Nadolol—Nausea—Alitretinoin—hematologic cancer	6.14e-05	0.000195	CcSEcCtD
Nadolol—Visual impairment—Epirubicin—hematologic cancer	6.14e-05	0.000195	CcSEcCtD
Nadolol—Agranulocytosis—Doxorubicin—hematologic cancer	6.12e-05	0.000194	CcSEcCtD
Nadolol—Hypertension—Prednisone—hematologic cancer	6.12e-05	0.000194	CcSEcCtD
Nadolol—Rash—Irinotecan—hematologic cancer	6.12e-05	0.000194	CcSEcCtD
Nadolol—Rash—Mitoxantrone—hematologic cancer	6.12e-05	0.000194	CcSEcCtD
Nadolol—Dermatitis—Irinotecan—hematologic cancer	6.11e-05	0.000194	CcSEcCtD
Nadolol—Dermatitis—Mitoxantrone—hematologic cancer	6.11e-05	0.000194	CcSEcCtD
Nadolol—Nausea—Ifosfamide—hematologic cancer	6.07e-05	0.000192	CcSEcCtD
Nadolol—Diarrhoea—Cisplatin—hematologic cancer	6.03e-05	0.000191	CcSEcCtD
Nadolol—Alopecia—Methotrexate—hematologic cancer	6.01e-05	0.000191	CcSEcCtD
Nadolol—Vomiting—Gemcitabine—hematologic cancer	6.01e-05	0.00019	CcSEcCtD
Nadolol—Insomnia—Dexamethasone—hematologic cancer	6.01e-05	0.00019	CcSEcCtD
Nadolol—Insomnia—Betamethasone—hematologic cancer	6.01e-05	0.00019	CcSEcCtD
Nadolol—Bradycardia—Doxorubicin—hematologic cancer	6e-05	0.00019	CcSEcCtD
Nadolol—Paraesthesia—Dexamethasone—hematologic cancer	5.96e-05	0.000189	CcSEcCtD
Nadolol—Paraesthesia—Betamethasone—hematologic cancer	5.96e-05	0.000189	CcSEcCtD
Nadolol—Rash—Gemcitabine—hematologic cancer	5.96e-05	0.000189	CcSEcCtD
Nadolol—Dermatitis—Gemcitabine—hematologic cancer	5.95e-05	0.000189	CcSEcCtD
Nadolol—Tinnitus—Epirubicin—hematologic cancer	5.94e-05	0.000188	CcSEcCtD
Nadolol—Nausea—Vincristine—hematologic cancer	5.92e-05	0.000188	CcSEcCtD
Nadolol—Dyspepsia—Dexamethasone—hematologic cancer	5.85e-05	0.000185	CcSEcCtD
Nadolol—Dyspepsia—Betamethasone—hematologic cancer	5.85e-05	0.000185	CcSEcCtD
Nadolol—Asthenia—Etoposide—hematologic cancer	5.79e-05	0.000184	CcSEcCtD
Nadolol—Body temperature increased—Triamcinolone—hematologic cancer	5.79e-05	0.000183	CcSEcCtD
Nadolol—Oedema—Prednisone—hematologic cancer	5.78e-05	0.000183	CcSEcCtD
Nadolol—Decreased appetite—Dexamethasone—hematologic cancer	5.77e-05	0.000183	CcSEcCtD
Nadolol—Decreased appetite—Betamethasone—hematologic cancer	5.77e-05	0.000183	CcSEcCtD
Nadolol—Nausea—Irinotecan—hematologic cancer	5.76e-05	0.000183	CcSEcCtD
Nadolol—Nausea—Mitoxantrone—hematologic cancer	5.76e-05	0.000183	CcSEcCtD
Nadolol—Fatigue—Betamethasone—hematologic cancer	5.73e-05	0.000182	CcSEcCtD
Nadolol—Fatigue—Dexamethasone—hematologic cancer	5.73e-05	0.000182	CcSEcCtD
Nadolol—Pruritus—Etoposide—hematologic cancer	5.71e-05	0.000181	CcSEcCtD
Nadolol—Shock—Prednisone—hematologic cancer	5.69e-05	0.00018	CcSEcCtD
Nadolol—Pain—Dexamethasone—hematologic cancer	5.68e-05	0.00018	CcSEcCtD
Nadolol—Pain—Betamethasone—hematologic cancer	5.68e-05	0.00018	CcSEcCtD
Nadolol—Visual impairment—Doxorubicin—hematologic cancer	5.68e-05	0.00018	CcSEcCtD
Nadolol—Alopecia—Epirubicin—hematologic cancer	5.63e-05	0.000178	CcSEcCtD
Nadolol—Nausea—Gemcitabine—hematologic cancer	5.61e-05	0.000178	CcSEcCtD
Nadolol—Vomiting—Cisplatin—hematologic cancer	5.6e-05	0.000178	CcSEcCtD
Nadolol—Hyperhidrosis—Prednisone—hematologic cancer	5.59e-05	0.000177	CcSEcCtD
Nadolol—Vision blurred—Methotrexate—hematologic cancer	5.58e-05	0.000177	CcSEcCtD
Nadolol—Rash—Cisplatin—hematologic cancer	5.55e-05	0.000176	CcSEcCtD
Nadolol—Dermatitis—Cisplatin—hematologic cancer	5.55e-05	0.000176	CcSEcCtD
Nadolol—Diarrhoea—Etoposide—hematologic cancer	5.52e-05	0.000175	CcSEcCtD
Nadolol—Anorexia—Prednisone—hematologic cancer	5.51e-05	0.000175	CcSEcCtD
Nadolol—Tinnitus—Doxorubicin—hematologic cancer	5.49e-05	0.000174	CcSEcCtD
Nadolol—Flatulence—Epirubicin—hematologic cancer	5.46e-05	0.000173	CcSEcCtD
Nadolol—Dizziness—Etoposide—hematologic cancer	5.34e-05	0.000169	CcSEcCtD
Nadolol—Dizziness—Prednisolone—hematologic cancer	5.26e-05	0.000167	CcSEcCtD
Nadolol—Asthenia—Triamcinolone—hematologic cancer	5.25e-05	0.000166	CcSEcCtD
Nadolol—Body temperature increased—Betamethasone—hematologic cancer	5.25e-05	0.000166	CcSEcCtD
Nadolol—Body temperature increased—Dexamethasone—hematologic cancer	5.25e-05	0.000166	CcSEcCtD
Nadolol—Nausea—Cisplatin—hematologic cancer	5.23e-05	0.000166	CcSEcCtD
Nadolol—Insomnia—Prednisone—hematologic cancer	5.23e-05	0.000166	CcSEcCtD
Nadolol—Vision blurred—Epirubicin—hematologic cancer	5.22e-05	0.000166	CcSEcCtD
Nadolol—Alopecia—Doxorubicin—hematologic cancer	5.21e-05	0.000165	CcSEcCtD
Nadolol—Paraesthesia—Prednisone—hematologic cancer	5.19e-05	0.000165	CcSEcCtD
Nadolol—Pruritus—Triamcinolone—hematologic cancer	5.18e-05	0.000164	CcSEcCtD
Nadolol—Cough—Methotrexate—hematologic cancer	5.17e-05	0.000164	CcSEcCtD
Nadolol—Vomiting—Etoposide—hematologic cancer	5.13e-05	0.000163	CcSEcCtD
Nadolol—Dyspepsia—Prednisone—hematologic cancer	5.09e-05	0.000161	CcSEcCtD
Nadolol—Rash—Etoposide—hematologic cancer	5.09e-05	0.000161	CcSEcCtD
Nadolol—Dermatitis—Etoposide—hematologic cancer	5.08e-05	0.000161	CcSEcCtD
Nadolol—Flatulence—Doxorubicin—hematologic cancer	5.05e-05	0.00016	CcSEcCtD
Nadolol—Chest pain—Methotrexate—hematologic cancer	5.04e-05	0.00016	CcSEcCtD
Nadolol—Decreased appetite—Prednisone—hematologic cancer	5.03e-05	0.000159	CcSEcCtD
Nadolol—Rash—Prednisolone—hematologic cancer	5.02e-05	0.000159	CcSEcCtD
Nadolol—Dermatitis—Prednisolone—hematologic cancer	5.01e-05	0.000159	CcSEcCtD
Nadolol—Fatigue—Prednisone—hematologic cancer	4.99e-05	0.000158	CcSEcCtD
Nadolol—Syncope—Epirubicin—hematologic cancer	4.97e-05	0.000158	CcSEcCtD
Nadolol—Constipation—Prednisone—hematologic cancer	4.95e-05	0.000157	CcSEcCtD
Nadolol—Loss of consciousness—Epirubicin—hematologic cancer	4.87e-05	0.000154	CcSEcCtD
Nadolol—Dizziness—Triamcinolone—hematologic cancer	4.84e-05	0.000153	CcSEcCtD
Nadolol—Cough—Epirubicin—hematologic cancer	4.84e-05	0.000153	CcSEcCtD
Nadolol—Vision blurred—Doxorubicin—hematologic cancer	4.83e-05	0.000153	CcSEcCtD
Nadolol—Nausea—Etoposide—hematologic cancer	4.79e-05	0.000152	CcSEcCtD
Nadolol—Hypertension—Epirubicin—hematologic cancer	4.79e-05	0.000152	CcSEcCtD
Nadolol—Asthenia—Dexamethasone—hematologic cancer	4.76e-05	0.000151	CcSEcCtD
Nadolol—Asthenia—Betamethasone—hematologic cancer	4.76e-05	0.000151	CcSEcCtD
Nadolol—Nausea—Prednisolone—hematologic cancer	4.73e-05	0.00015	CcSEcCtD
Nadolol—Chest pain—Epirubicin—hematologic cancer	4.72e-05	0.00015	CcSEcCtD
Nadolol—Pruritus—Betamethasone—hematologic cancer	4.7e-05	0.000149	CcSEcCtD
Nadolol—Pruritus—Dexamethasone—hematologic cancer	4.7e-05	0.000149	CcSEcCtD
Nadolol—Hyperhidrosis—Methotrexate—hematologic cancer	4.67e-05	0.000148	CcSEcCtD
Nadolol—Vomiting—Triamcinolone—hematologic cancer	4.65e-05	0.000148	CcSEcCtD
Nadolol—Rash—Triamcinolone—hematologic cancer	4.61e-05	0.000146	CcSEcCtD
Nadolol—Dry mouth—Epirubicin—hematologic cancer	4.61e-05	0.000146	CcSEcCtD
Nadolol—Dermatitis—Triamcinolone—hematologic cancer	4.61e-05	0.000146	CcSEcCtD
Nadolol—Anorexia—Methotrexate—hematologic cancer	4.61e-05	0.000146	CcSEcCtD
Nadolol—Syncope—Doxorubicin—hematologic cancer	4.6e-05	0.000146	CcSEcCtD
Nadolol—Body temperature increased—Prednisone—hematologic cancer	4.57e-05	0.000145	CcSEcCtD
Nadolol—Diarrhoea—Betamethasone—hematologic cancer	4.54e-05	0.000144	CcSEcCtD
Nadolol—Diarrhoea—Dexamethasone—hematologic cancer	4.54e-05	0.000144	CcSEcCtD
Nadolol—Oedema—Epirubicin—hematologic cancer	4.52e-05	0.000143	CcSEcCtD
Nadolol—Hypotension—Methotrexate—hematologic cancer	4.52e-05	0.000143	CcSEcCtD
Nadolol—Loss of consciousness—Doxorubicin—hematologic cancer	4.51e-05	0.000143	CcSEcCtD
Nadolol—Cough—Doxorubicin—hematologic cancer	4.48e-05	0.000142	CcSEcCtD
Nadolol—Shock—Epirubicin—hematologic cancer	4.45e-05	0.000141	CcSEcCtD
Nadolol—Hypertension—Doxorubicin—hematologic cancer	4.43e-05	0.00014	CcSEcCtD
Nadolol—Dizziness—Betamethasone—hematologic cancer	4.39e-05	0.000139	CcSEcCtD
Nadolol—Dizziness—Dexamethasone—hematologic cancer	4.39e-05	0.000139	CcSEcCtD
Nadolol—Hyperhidrosis—Epirubicin—hematologic cancer	4.37e-05	0.000139	CcSEcCtD
Nadolol—Insomnia—Methotrexate—hematologic cancer	4.37e-05	0.000139	CcSEcCtD
Nadolol—Chest pain—Doxorubicin—hematologic cancer	4.37e-05	0.000138	CcSEcCtD
Nadolol—Nausea—Triamcinolone—hematologic cancer	4.35e-05	0.000138	CcSEcCtD
Nadolol—Paraesthesia—Methotrexate—hematologic cancer	4.34e-05	0.000138	CcSEcCtD
Nadolol—Anorexia—Epirubicin—hematologic cancer	4.31e-05	0.000137	CcSEcCtD
Nadolol—Dyspnoea—Methotrexate—hematologic cancer	4.31e-05	0.000137	CcSEcCtD
Nadolol—Dry mouth—Doxorubicin—hematologic cancer	4.27e-05	0.000135	CcSEcCtD
Nadolol—Dyspepsia—Methotrexate—hematologic cancer	4.25e-05	0.000135	CcSEcCtD
Nadolol—Hypotension—Epirubicin—hematologic cancer	4.23e-05	0.000134	CcSEcCtD
Nadolol—Vomiting—Dexamethasone—hematologic cancer	4.22e-05	0.000134	CcSEcCtD
Nadolol—Vomiting—Betamethasone—hematologic cancer	4.22e-05	0.000134	CcSEcCtD
Nadolol—Decreased appetite—Methotrexate—hematologic cancer	4.2e-05	0.000133	CcSEcCtD
Nadolol—Rash—Dexamethasone—hematologic cancer	4.19e-05	0.000133	CcSEcCtD
Nadolol—Rash—Betamethasone—hematologic cancer	4.19e-05	0.000133	CcSEcCtD
Nadolol—Oedema—Doxorubicin—hematologic cancer	4.19e-05	0.000133	CcSEcCtD
Nadolol—Dermatitis—Betamethasone—hematologic cancer	4.18e-05	0.000133	CcSEcCtD
Nadolol—Dermatitis—Dexamethasone—hematologic cancer	4.18e-05	0.000133	CcSEcCtD
Nadolol—Fatigue—Methotrexate—hematologic cancer	4.17e-05	0.000132	CcSEcCtD
Nadolol—Asthenia—Prednisone—hematologic cancer	4.15e-05	0.000132	CcSEcCtD
Nadolol—Pain—Methotrexate—hematologic cancer	4.13e-05	0.000131	CcSEcCtD
Nadolol—Shock—Doxorubicin—hematologic cancer	4.12e-05	0.000131	CcSEcCtD
Nadolol—Pruritus—Prednisone—hematologic cancer	4.09e-05	0.00013	CcSEcCtD
Nadolol—Insomnia—Epirubicin—hematologic cancer	4.09e-05	0.00013	CcSEcCtD
Nadolol—Paraesthesia—Epirubicin—hematologic cancer	4.06e-05	0.000129	CcSEcCtD
Nadolol—Hyperhidrosis—Doxorubicin—hematologic cancer	4.05e-05	0.000128	CcSEcCtD
Nadolol—Dyspnoea—Epirubicin—hematologic cancer	4.03e-05	0.000128	CcSEcCtD
Nadolol—Anorexia—Doxorubicin—hematologic cancer	3.99e-05	0.000126	CcSEcCtD
Nadolol—Dyspepsia—Epirubicin—hematologic cancer	3.98e-05	0.000126	CcSEcCtD
Nadolol—Diarrhoea—Prednisone—hematologic cancer	3.96e-05	0.000125	CcSEcCtD
Nadolol—Nausea—Dexamethasone—hematologic cancer	3.94e-05	0.000125	CcSEcCtD
Nadolol—Nausea—Betamethasone—hematologic cancer	3.94e-05	0.000125	CcSEcCtD
Nadolol—Decreased appetite—Epirubicin—hematologic cancer	3.93e-05	0.000125	CcSEcCtD
Nadolol—Hypotension—Doxorubicin—hematologic cancer	3.91e-05	0.000124	CcSEcCtD
Nadolol—Fatigue—Epirubicin—hematologic cancer	3.9e-05	0.000124	CcSEcCtD
Nadolol—Pain—Epirubicin—hematologic cancer	3.87e-05	0.000123	CcSEcCtD
Nadolol—Constipation—Epirubicin—hematologic cancer	3.87e-05	0.000123	CcSEcCtD
Nadolol—Dizziness—Prednisone—hematologic cancer	3.82e-05	0.000121	CcSEcCtD
Nadolol—Body temperature increased—Methotrexate—hematologic cancer	3.82e-05	0.000121	CcSEcCtD
Nadolol—Insomnia—Doxorubicin—hematologic cancer	3.79e-05	0.00012	CcSEcCtD
Nadolol—Paraesthesia—Doxorubicin—hematologic cancer	3.76e-05	0.000119	CcSEcCtD
Nadolol—Dyspnoea—Doxorubicin—hematologic cancer	3.73e-05	0.000118	CcSEcCtD
Nadolol—Dyspepsia—Doxorubicin—hematologic cancer	3.68e-05	0.000117	CcSEcCtD
Nadolol—Vomiting—Prednisone—hematologic cancer	3.68e-05	0.000117	CcSEcCtD
Nadolol—Rash—Prednisone—hematologic cancer	3.65e-05	0.000116	CcSEcCtD
Nadolol—Dermatitis—Prednisone—hematologic cancer	3.64e-05	0.000115	CcSEcCtD
Nadolol—Decreased appetite—Doxorubicin—hematologic cancer	3.64e-05	0.000115	CcSEcCtD
Nadolol—Fatigue—Doxorubicin—hematologic cancer	3.61e-05	0.000114	CcSEcCtD
Nadolol—Pain—Doxorubicin—hematologic cancer	3.58e-05	0.000113	CcSEcCtD
Nadolol—Constipation—Doxorubicin—hematologic cancer	3.58e-05	0.000113	CcSEcCtD
Nadolol—Body temperature increased—Epirubicin—hematologic cancer	3.58e-05	0.000113	CcSEcCtD
Nadolol—Asthenia—Methotrexate—hematologic cancer	3.47e-05	0.00011	CcSEcCtD
Nadolol—Nausea—Prednisone—hematologic cancer	3.44e-05	0.000109	CcSEcCtD
Nadolol—Pruritus—Methotrexate—hematologic cancer	3.42e-05	0.000108	CcSEcCtD
Nadolol—Body temperature increased—Doxorubicin—hematologic cancer	3.31e-05	0.000105	CcSEcCtD
Nadolol—Diarrhoea—Methotrexate—hematologic cancer	3.31e-05	0.000105	CcSEcCtD
Nadolol—Asthenia—Epirubicin—hematologic cancer	3.25e-05	0.000103	CcSEcCtD
Nadolol—Pruritus—Epirubicin—hematologic cancer	3.2e-05	0.000101	CcSEcCtD
Nadolol—Dizziness—Methotrexate—hematologic cancer	3.2e-05	0.000101	CcSEcCtD
Nadolol—Diarrhoea—Epirubicin—hematologic cancer	3.09e-05	9.81e-05	CcSEcCtD
Nadolol—Vomiting—Methotrexate—hematologic cancer	3.07e-05	9.74e-05	CcSEcCtD
Nadolol—Rash—Methotrexate—hematologic cancer	3.05e-05	9.66e-05	CcSEcCtD
Nadolol—Dermatitis—Methotrexate—hematologic cancer	3.04e-05	9.65e-05	CcSEcCtD
Nadolol—Asthenia—Doxorubicin—hematologic cancer	3e-05	9.52e-05	CcSEcCtD
Nadolol—Dizziness—Epirubicin—hematologic cancer	2.99e-05	9.48e-05	CcSEcCtD
Nadolol—Pruritus—Doxorubicin—hematologic cancer	2.96e-05	9.39e-05	CcSEcCtD
Nadolol—Vomiting—Epirubicin—hematologic cancer	2.88e-05	9.12e-05	CcSEcCtD
Nadolol—Nausea—Methotrexate—hematologic cancer	2.87e-05	9.1e-05	CcSEcCtD
Nadolol—Diarrhoea—Doxorubicin—hematologic cancer	2.86e-05	9.08e-05	CcSEcCtD
Nadolol—Rash—Epirubicin—hematologic cancer	2.85e-05	9.04e-05	CcSEcCtD
Nadolol—Dermatitis—Epirubicin—hematologic cancer	2.85e-05	9.03e-05	CcSEcCtD
Nadolol—Dizziness—Doxorubicin—hematologic cancer	2.77e-05	8.77e-05	CcSEcCtD
Nadolol—Nausea—Epirubicin—hematologic cancer	2.69e-05	8.52e-05	CcSEcCtD
Nadolol—Vomiting—Doxorubicin—hematologic cancer	2.66e-05	8.44e-05	CcSEcCtD
Nadolol—Rash—Doxorubicin—hematologic cancer	2.64e-05	8.37e-05	CcSEcCtD
Nadolol—Dermatitis—Doxorubicin—hematologic cancer	2.64e-05	8.36e-05	CcSEcCtD
Nadolol—Nausea—Doxorubicin—hematologic cancer	2.49e-05	7.88e-05	CcSEcCtD
Nadolol—ADRB3—Signaling Pathways—BRAF—hematologic cancer	1.37e-05	0.00019	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL2—hematologic cancer	1.37e-05	0.000189	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CREB1—hematologic cancer	1.37e-05	0.000189	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6R—hematologic cancer	1.36e-05	0.000189	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL2—hematologic cancer	1.36e-05	0.000188	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6R—hematologic cancer	1.36e-05	0.000188	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CREBBP—hematologic cancer	1.36e-05	0.000187	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.35e-05	0.000187	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT1—hematologic cancer	1.35e-05	0.000187	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SLC22A1—hematologic cancer	1.35e-05	0.000186	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CRABP1—hematologic cancer	1.35e-05	0.000186	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3R1—hematologic cancer	1.34e-05	0.000186	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	1.34e-05	0.000185	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	1.33e-05	0.000185	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	1.31e-05	0.000182	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALOX5—hematologic cancer	1.31e-05	0.000181	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.31e-05	0.000181	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	1.3e-05	0.00018	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	1.3e-05	0.00018	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAP2K1—hematologic cancer	1.29e-05	0.000179	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GRB2—hematologic cancer	1.29e-05	0.000179	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	1.29e-05	0.000179	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	1.29e-05	0.000178	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CD—hematologic cancer	1.28e-05	0.000178	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	1.28e-05	0.000177	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PIK3CA—hematologic cancer	1.27e-05	0.000176	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KITLG—hematologic cancer	1.27e-05	0.000176	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	1.27e-05	0.000176	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NUP98—hematologic cancer	1.27e-05	0.000176	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	1.26e-05	0.000175	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	1.26e-05	0.000175	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	1.26e-05	0.000175	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—KRAS—hematologic cancer	1.26e-05	0.000174	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	1.24e-05	0.000172	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	1.24e-05	0.000172	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	1.24e-05	0.000171	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ADCY7—hematologic cancer	1.23e-05	0.00017	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOA3—hematologic cancer	1.23e-05	0.00017	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	1.23e-05	0.00017	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FGF2—hematologic cancer	1.23e-05	0.00017	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NUP214—hematologic cancer	1.22e-05	0.000169	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	1.22e-05	0.000169	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	1.22e-05	0.000168	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3R1—hematologic cancer	1.21e-05	0.000168	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	1.21e-05	0.000168	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	1.2e-05	0.000167	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTR—hematologic cancer	1.2e-05	0.000166	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ABCG2—hematologic cancer	1.2e-05	0.000166	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	1.19e-05	0.000165	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CD86—hematologic cancer	1.19e-05	0.000165	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	1.18e-05	0.000164	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—JAK2—hematologic cancer	1.18e-05	0.000163	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ENO2—hematologic cancer	1.18e-05	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HES1—hematologic cancer	1.17e-05	0.000163	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	1.17e-05	0.000162	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CD86—hematologic cancer	1.17e-05	0.000161	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	1.16e-05	0.00016	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PIK3CA—hematologic cancer	1.16e-05	0.00016	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	1.16e-05	0.00016	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	1.16e-05	0.00016	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MDM2—hematologic cancer	1.15e-05	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HES1—hematologic cancer	1.15e-05	0.000159	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	1.14e-05	0.000158	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTT1—hematologic cancer	1.14e-05	0.000158	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	1.14e-05	0.000157	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	1.14e-05	0.000157	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	1.14e-05	0.000157	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	1.13e-05	0.000156	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	1.13e-05	0.000156	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	1.13e-05	0.000156	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MTOR—hematologic cancer	1.12e-05	0.000155	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CB—hematologic cancer	1.12e-05	0.000155	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	1.12e-05	0.000155	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	1.11e-05	0.000154	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	1.11e-05	0.000154	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SDC1—hematologic cancer	1.11e-05	0.000154	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	1.11e-05	0.000154	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	1.11e-05	0.000154	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	1.11e-05	0.000154	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.11e-05	0.000153	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	1.1e-05	0.000152	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	1.09e-05	0.000151	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	1.09e-05	0.000151	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	1.09e-05	0.000151	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—HRAS—hematologic cancer	1.07e-05	0.000148	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.07e-05	0.000148	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1B—hematologic cancer	1.05e-05	0.000145	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	1.04e-05	0.000144	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—AKT1—hematologic cancer	1.04e-05	0.000144	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	1.03e-05	0.000143	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CASP3—hematologic cancer	1.03e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TERT—hematologic cancer	1.03e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL2—hematologic cancer	1.03e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—hematologic cancer	1.02e-05	0.000142	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	1.02e-05	0.000141	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	1.01e-05	0.00014	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TERT—hematologic cancer	1.01e-05	0.000139	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	1e-05	0.000139	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCND1—hematologic cancer	1e-05	0.000139	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—JUN—hematologic cancer	1e-05	0.000138	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	9.99e-06	0.000138	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	9.83e-06	0.000136	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	9.82e-06	0.000136	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CDKN1A—hematologic cancer	9.7e-06	0.000134	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTEN—hematologic cancer	9.68e-06	0.000134	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	9.61e-06	0.000133	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CD44—hematologic cancer	9.48e-06	0.000131	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NQO1—hematologic cancer	9.48e-06	0.000131	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK8—hematologic cancer	9.47e-06	0.000131	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	9.45e-06	0.000131	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—AKT1—hematologic cancer	9.44e-06	0.000131	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	9.35e-06	0.000129	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	9.24e-06	0.000128	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EP300—hematologic cancer	9.23e-06	0.000128	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	9.18e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	9.15e-06	0.000127	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FN1—hematologic cancer	9.06e-06	0.000125	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	8.98e-06	0.000124	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SRC—hematologic cancer	8.97e-06	0.000124	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYCS—hematologic cancer	8.97e-06	0.000124	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BAD—hematologic cancer	8.96e-06	0.000124	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	8.96e-06	0.000124	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HSP90AA1—hematologic cancer	8.91e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	8.87e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FN1—hematologic cancer	8.87e-06	0.000123	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BAD—hematologic cancer	8.76e-06	0.000121	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	8.76e-06	0.000121	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—hematologic cancer	8.74e-06	0.000121	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CD80—hematologic cancer	8.69e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	8.68e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	8.67e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KIT—hematologic cancer	8.67e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	8.67e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—hematologic cancer	8.65e-06	0.00012	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NRAS—hematologic cancer	8.63e-06	0.000119	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	8.52e-06	0.000118	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CD80—hematologic cancer	8.5e-06	0.000118	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KIT—hematologic cancer	8.49e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	8.49e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	8.49e-06	0.000117	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	8.34e-06	0.000115	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	8.31e-06	0.000115	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK3—hematologic cancer	8.27e-06	0.000114	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	8.26e-06	0.000114	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	8.15e-06	0.000113	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	8.13e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	8.08e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	8.08e-06	0.000112	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	8.05e-06	0.000111	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	8.04e-06	0.000111	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—hematologic cancer	8.04e-06	0.000111	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—hematologic cancer	8.02e-06	0.000111	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	7.98e-06	0.00011	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTP1—hematologic cancer	7.9e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	7.9e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	7.88e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	7.87e-06	0.000109	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	7.68e-06	0.000106	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	7.63e-06	0.000105	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.55e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	7.51e-06	0.000104	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	7.47e-06	0.000103	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	7.46e-06	0.000103	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KRAS—hematologic cancer	7.43e-06	0.000103	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	7.39e-06	0.000102	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	7.3e-06	0.000101	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	7.3e-06	0.000101	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NCOR1—hematologic cancer	7.26e-06	0.0001	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTM1—hematologic cancer	7.26e-06	0.0001	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	7.2e-06	9.96e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	7.14e-06	9.88e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	7.04e-06	9.74e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	7e-06	9.68e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	6.86e-06	9.49e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	6.85e-06	9.47e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	6.83e-06	9.45e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PIK3CA—hematologic cancer	6.83e-06	9.44e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	6.71e-06	9.28e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	6.68e-06	9.24e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	6.65e-06	9.19e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	6.65e-06	9.19e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—hematologic cancer	6.6e-06	9.14e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	6.5e-06	8.99e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	6.5e-06	8.99e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MTHFR—hematologic cancer	6.42e-06	8.88e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	6.35e-06	8.78e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HRAS—hematologic cancer	6.32e-06	8.74e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	6.24e-06	8.63e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	6.21e-06	8.59e-05	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	6.17e-06	8.54e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	6.11e-06	8.46e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	6.1e-06	8.44e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	6.1e-06	8.44e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	6.07e-06	8.4e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—hematologic cancer	6.05e-06	8.36e-05	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	6.04e-06	8.35e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	5.98e-06	8.27e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	5.97e-06	8.26e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	5.95e-06	8.23e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	5.94e-06	8.22e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	5.94e-06	8.21e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	5.82e-06	8.05e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	5.81e-06	8.04e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	5.76e-06	7.96e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	5.74e-06	7.95e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	5.63e-06	7.79e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	5.62e-06	7.77e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	5.62e-06	7.77e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	5.6e-06	7.75e-05	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—AKT1—hematologic cancer	5.58e-06	7.71e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	5.5e-06	7.6e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	5.48e-06	7.58e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	5.48e-06	7.58e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CG—hematologic cancer	5.39e-06	7.46e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	5.36e-06	7.41e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	5.33e-06	7.37e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	5.21e-06	7.21e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	5.19e-06	7.18e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	5.14e-06	7.11e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	5.12e-06	7.09e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	5.07e-06	7.02e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	5.02e-06	6.95e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	5.01e-06	6.93e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CREBBP—hematologic cancer	5e-06	6.92e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	4.91e-06	6.79e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	4.8e-06	6.64e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	4.77e-06	6.6e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	4.76e-06	6.59e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CD—hematologic cancer	4.74e-06	6.56e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—hematologic cancer	4.68e-06	6.47e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	4.67e-06	6.46e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	4.66e-06	6.44e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3R1—hematologic cancer	4.48e-06	6.19e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	4.41e-06	6.1e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	4.31e-06	5.97e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CB—hematologic cancer	4.13e-06	5.72e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	4.05e-06	5.61e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	3.96e-06	5.48e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	3.92e-06	5.42e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	3.83e-06	5.3e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	3.75e-06	5.19e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	3.67e-06	5.07e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	3.59e-06	4.96e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PTEN—hematologic cancer	3.57e-06	4.94e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	3.51e-06	4.86e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—EP300—hematologic cancer	3.41e-06	4.71e-05	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	3.31e-06	4.58e-05	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	3.24e-06	4.48e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—PIK3CA—hematologic cancer	2.52e-06	3.48e-05	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—AKT1—hematologic cancer	2.06e-06	2.85e-05	CbGpPWpGaD
